Navigation Links
Rubicon Genomics Announces a Licensing Agreement With Abbott to Develop and Commercialize DNA Methylation Cancer Tests
Date:1/12/2009

ANN ARBOR, Mich., Jan. 12 /PRNewswire/ -- Rubicon Genomics today announced a licensing agreement with Abbott, which marks the achievement of significant milestones within their on-going Research and Option Agreement for development and commercialization of Rubicon MethylPlex(TM) methylation detection technology for the diagnosis and prognosis of cancer.

Under the terms of the agreement Abbott receives a non-exclusive license to MethylPlex for in vitro molecular diagnostics to detect the presence or risk of prostate, bladder and colon cancer for screening and non-screening indications. Abbott also obtains a non-exclusive license for non-screening applications with other diseases and options to colon cancer biomarkers developed in collaboration with Rubicon.

"This license is a significant validation of the MethylPlex technology as an effective, simple, automatable method for detecting cancer using DNA methylation in patient plasma," said James Koziarz, Acting President and CEO of Rubicon. Mr. Koziarz went on to say, "The collaboration between Rubicon and Abbott has been very productive with both parties making significant contributions towards development and commercialization of IVD products that employ MethylPlex biomarkers and assays. We look forward to continuing our joint efforts under our collaboration and developing leading edge products."

About Rubicon Genomics, Inc.

Rubicon, located in Ann Arbor, MI, is a pre-analytical platform company that has developed and commercialized reagents and kits to increase the analytical and clinical performance of analytical platforms including Q-PCR, microarrays, and next-gen sequencing. Its GenomePlex(TM), TransPlex(TM), and MethylPlex(TM) products achieve unbiased amplification and standardization of total DNA, total RNA, and methylated DNA. By producing highly pure DNA of uniform concentration and molecular weight these products increase the sensi
'/>"/>

SOURCE Rubicon Genomics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Nutrigenomics - Developing Personalized Diets for Disease Prevention - Is the Focus of a Special Issue of OMICS
2. Rosetta Genomics to Present at Rodman & Renshaw 10th Annual Healthcare Conference
3. NeoGenomics Schedules Its Q3 2008 Earnings Release for November 6, 2008
4. UC San Diego to lead nationwide program in pharmacogenomics
5. NeoGenomics to Present at the Noble Financial Equity Conference
6. NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008
7. AutoGenomics, Inc. Files Registration Statement for Initial Public Offering
8. AutoGenomics INFINITI Analyzer Receives Artistic Design Award
9. AutoGenomics Receives a Key European Patent for HPV Detection
10. Genomics of Cardiovascular Disease: Current Clinical Applications
11. Navigenics Proposes Standards for Personal Genomics Services, Coupled With Prospective Outcomes Studies, to Safeguard Consumers

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)... Tomorrow may be too late ...s condition, according to TOPS Club, Inc. (Take Of...ort organization. , (Vocu...en it comes to preventing or improving a diabetes ...Pounds Sensibly), the nonprofit weight-loss suppor...
(Date:11/9/2009)..., The National Comprehensive Cancer Network (NC...ent that details a draft paradigm for near-term co... upon existing data. The document introduces the N...sensus-based process that compares the risk-versus...d in the NCCN Clinical Practice Guidelines in Onco...
(Date:11/9/2009)..., March of Dimes Names 2010 National Ambassad...USNewswire/ -- Joshua Hoffman of Weston, Fla., was...ans that doctors could not say whether he would su...ar. Today, the 6-year-old was named March of Dimes...lanie Hoffman, recalls, "My first minutes of mothe...
(Date:11/9/2009)..., NEW YORK, Nov. 9 Th...l make its world television debut on the Sundance ...8 p.m. EST/PST. ,, Directed by Academy Award&#...journeys of children with type 1 diabetes amid the...one the world,s poorest countries. The children ar...
(Date:11/9/2009)..., NEW YORK, Nov. 9 /PRNewswire/ -- Phoenix ...nd drug abuse treatment and prevention program, an...., a nationally and internationally recognized lea...Chief Clinical Officer, effective January 1, 2010.... of substance abuse treatment research and her wor...
Breaking Medicine News(10 mins):Health News:Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says 2Health News:Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says 3Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 2Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 3Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 4Health News:Six-Year-Old Survivor Fights for Preemies Like Himself 2Health News:Six-Year-Old Survivor Fights for Preemies Like Himself 3Health News:Award-winning Diabetes Documentary to Make World TV Premiere on Sundance Channel on World Diabetes Day 2Health News:Award-winning Diabetes Documentary to Make World TV Premiere on Sundance Channel on World Diabetes Day 3Health News:Award-winning Diabetes Documentary to Make World TV Premiere on Sundance Channel on World Diabetes Day 4Health News:Award-winning Diabetes Documentary to Make World TV Premiere on Sundance Channel on World Diabetes Day 5Health News:Award-winning Diabetes Documentary to Make World TV Premiere on Sundance Channel on World Diabetes Day 6Health News:Phoenix House Appoints Dr. Deni Carise as Chief Clinical Officer - Internationally Recognized Leader in Substance Abuse Treatment and Research 2Health News:Phoenix House Appoints Dr. Deni Carise as Chief Clinical Officer - Internationally Recognized Leader in Substance Abuse Treatment and Research 3
... strategic fit with highly complementary businesse...pend Management - $12-14 million of expecte...ted to be accretive to earnings per share in 2009,...d National Medical Health Card Systems, Inc. ("NMH...
...k Exchange Symbol: CYT ...ewswire-FirstCall/ - CryoCath(R) Technologies,Inc....at cardiac,arrhythmias, today announced that Chief...hief Financial Officer at,CryoCath. Mr. Lindsay ha...
...ORONTO, Feb. 26 /PRNewswire-FirstCall/ - Bradmer P...dicated to the development and,commercialization o...data,on the Company,s Neuradiab product candidate ...g/cgi/rapidpdf/15228517-2007-053v1 ),This report s...
...nn., Feb. 26 Construction is,underway to expand T...ng,the size of the six-year-old location. When com... exam and procedure rooms, improved privacy for,in...cal staff, including cardiovascular surgery, which...
.... 26 Carriage Services, Inc.,(NYSE: CSV ) today ...,year-end results on Thursday, March 6, 2008 after...e, Carriage Services has scheduled a conference,ca...07 Earnings Conference Call, When: Friday, March...
...cord Revenues of NIS 1.1 Billion With a 14% Rise i...s Merger Paying Off: Q4 Gross Margin of 33% & Rec... (Adjusted), PETACH TIKVA, Israel, February 26 ...ancial results for the fourth quarter and full yea...
Other Medicine News:Health News:SXC Health Solutions Corp. to acquire National Medical Health Card Systems, Inc. 2Health News:SXC Health Solutions Corp. to acquire National Medical Health Card Systems, Inc. 3Health News:SXC Health Solutions Corp. to acquire National Medical Health Card Systems, Inc. 4Health News:SXC Health Solutions Corp. to acquire National Medical Health Card Systems, Inc. 5Health News:SXC Health Solutions Corp. to acquire National Medical Health Card Systems, Inc. 6Health News:SXC Health Solutions Corp. to acquire National Medical Health Card Systems, Inc. 7Health News:SXC Health Solutions Corp. to acquire National Medical Health Card Systems, Inc. 8Health News:CryoCath Appoints New Chief Financial Officer 2Health News:Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study 2Health News:Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study 3Health News:Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study 4Health News:Expansion Will Double Size of The Heart Center at Regions Hospital 2Health News:Carriage Services Announces Fourth Quarter and Year-End Earnings Release and Conference Call Schedule 2Health News:012 Smile.Communications Reports Financial Results for Q4 and Full Year 2007 2Health News:012 Smile.Communications Reports Financial Results for Q4 and Full Year 2007 3Health News:012 Smile.Communications Reports Financial Results for Q4 and Full Year 2007 4Health News:012 Smile.Communications Reports Financial Results for Q4 and Full Year 2007 5Health News:012 Smile.Communications Reports Financial Results for Q4 and Full Year 2007 6Health News:012 Smile.Communications Reports Financial Results for Q4 and Full Year 2007 7Health News:012 Smile.Communications Reports Financial Results for Q4 and Full Year 2007 8Health News:012 Smile.Communications Reports Financial Results for Q4 and Full Year 2007 9Health News:012 Smile.Communications Reports Financial Results for Q4 and Full Year 2007 10Health News:012 Smile.Communications Reports Financial Results for Q4 and Full Year 2007 11Health News:012 Smile.Communications Reports Financial Results for Q4 and Full Year 2007 12
(Date:11/9/2009)...e/ -- Bend Research Inc., a company,with more than...rmaceutical,technologies to help clients solve the...s, announced today that it has entered into a coll..., a global biotechnology company,headquartered in ...ration, Vertex will utilize Bend,s formulation,dev...
(Date:11/9/2009)...- PAREXEL International Corporation (Nasdaq: PRXL...ovider, today announced that it has enhanced its c...l development through an alliance with Mortara Ins...electrocardiogram (ECG) devices and related techno...t,s Surveyor Telemetry Central System to supplemen...
(Date:11/9/2009)...rstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: ...or drug discovery and life sciences research, toda...nd Services (CDAS) unit has been awarded a new fun...t with the Environmental Protection Agency (EPA) f...task order increases the cumulative funding Calipe...
Breaking Medicine Technology:Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration 2Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration 3PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument 2PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument 3PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument 4PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument 5Caliper Awarded New Task Order for EPA ToxCast Program 2Caliper Awarded New Task Order for EPA ToxCast Program 3Micromet Announces Pricing of Public Offering of Common Stock 13287 1Micromet Announces Pricing of Public Offering of Common Stock 13287 2Micromet Announces Pricing of Public Offering of Common Stock 13287 3Micromet Announces Pricing of Public Offering of Common Stock 13287 4North American Spine Society Expresses Concern Over Proposed Federal Health Care Reform Legislation 53218 1North American Spine Society Expresses Concern Over Proposed Federal Health Care Reform Legislation 53218 2Breakthrough Nursing Home Alternative Now Available to Cincinnati Elders and Their Families at Deupree Cottages 53216 1Breakthrough Nursing Home Alternative Now Available to Cincinnati Elders and Their Families at Deupree Cottages 53216 2Breakthrough Nursing Home Alternative Now Available to Cincinnati Elders and Their Families at Deupree Cottages 53216 3
...gned to Determine Statin Effects on Regression of ...inic researchers will,coordinate the first head-to...edications. The trial intends to begin enrollment ...t commonly prescribed drugs and widely,used to tre...e two drugs, atorvastatin (Lipitor) and rosuvastat...
...alif., Jan. 15 Kosan Biosciences,Incorporated (Na...Phase 2,trial of alvespimycin, the company,s secon...2-positive metastatic breast cancer. Alvespimycin ...vity of multiple oncogenes,and cell signaling path...,key signaling pathway in breast cancer. The objec...
Other Medicine Technology:Cleveland Clinic to Lead First Head-to-Head Comparison of the Two Most Potent Statins 2Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer 2Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer 3Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer 4
Ralk Hand Drill
DeMartel (Bailey) Wire Saw Guide
Cranial Drill
Cone Skull Punch
Medicine Products: